The Commercial Trajectory of Bedaquiline, Pretomanid, and Linezolid...

Ajouter une nouvelle offre d'emploi Otro

2026-04-24 08:51:51 - Traduire

The Commercial Trajectory of Bedaquiline, Pretomanid, and Linezolid (BPaL): Analyzing 2026 Trends in Standardized Care (2026–2032)

Regional Overview of Executive Summary Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market by Size and Share The global extensively drug resistant tuberculosis (XDR-TB) treatment market size was valued at USD 947.79 million in 2024 and is expected to reach USD 1,541.69 million by 2032, at a CAGR of 6.27% during the forecast period...

0 Commentaires 0 Parts 35 Vue 0 Aperçu